Advertisement

PubMed

Off-label dermatologic uses of IL-23 inhibitors.

While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated...

Read More

For latest news and updates
Email-id is invalid